Officials at St. Jude announce that the company's renal denervation system lowered blood pressure at six months.
Targeting nerves in the renal arteries leading to the kidneys, the EnligHTN I study helped patients reduce their blood pressure 28 mmHg points after 30 days. That rate was kept up after six months, according to studies. Seventy-six percent of patients responded to the therapy, with blood pressure dropping from an average of 176/96 mmHg to 150/86 mmHg. No serious problems with the device or therapy were reported.
The EngligHTN system disrupts a network of nerves that controls blood pressure, a process which has been found to reduce systolic and diastolic blood pressure, according to the Star Tribune in Minnesota.
Latest from Today's Medical Developments
- Gore completes acquisition of Conformal Medical
- Medical textiles designed for cardiovascular, orthopedic, dental prosthetic applications
- Micro-precision 3D printing: Trends and breakthroughs in medical device manufacturing
- One-component, dual-cure adhesive system for medical device assembly
- #82 Manufacturing Matters - Forecasting 2026 with GIE Media's Manufacturing Group
- Flexing prosthetic finger offers lifelike appearance and movement
- How the fast-evolving defense market impacts suppliers
- Medtronic’s Hugo robotic-assisted surgery system makes US debut
